- Home
- BANC vs NVCR Comparison
BANC vs NVCR Comparison
Compare BANC & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BANC | NVCR |
|---|---|---|
| Founded | 1941 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.0B |
| IPO Year | 2002 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BANC | NVCR |
|---|---|---|
| Price | $17.49 | $15.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 7 |
| Target Price | $22.00 | ★ $27.14 |
| AVG Volume (30 Days) | ★ 2.0M | 881.8K |
| Earning Date | 10-21-2026 | 10-29-2026 |
| Dividend Yield | ★ 2.79% | N/A |
| EPS Growth | ★ 125.00 | 21.79 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,818,792,000.00 | $655,353,000.00 |
| Revenue This Year | $3.93 | $10.76 |
| Revenue Next Year | $11.48 | $10.88 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $15.33 | $9.82 |
| 52 Week High | $21.93 | $21.45 |
Technical Indicators
Market Signals| Indicator | BANC | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 27.73 | 47.89 |
| Support Level | $16.35 | $14.93 |
| Resistance Level | $19.16 | $18.43 |
| Average True Range (ATR) | 0.40 | 0.57 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 0.00 | 60.84 |
Price Performance
Historical ComparisonAbout BANC Banc of California Inc.
Banc of California Inc is a financial holding company. It offers banking and financial services. Its services include banking services, lending services, and private banking services. Its deposit and banking product and service offerings include checking, savings, money market, certificates of deposit, and retirement accounts. Lending activities are focused on providing financing to California's diverse private businesses, entrepreneurs, and communities, and loans are often secured by California commercial and residential real estate. The company has one reportable segment named Commercial banking.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.